Skip to content
Company Analysis

NovoCure Limited NVCR

A comprehensive view of key metrics, scores, and financial health for NovoCure Limited

Overview of NovoCure Limited

NVCR NMS
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Small Cap
NovoCure Limited (NVCR), is a Small Cap company, in the Medical Devices industry, last closed at $13.21, about 50.9% overvalued vs fair value, +17.2% 1Y return, ranked 460/1145 in sector.
Metrics Rev Growth 8.3% ROE -38.9% Gross Margin 74.5%
USD 13.21
0.46%
(Delayed)
• Vol 90d: 69.2%
52-Week Range
Market Cap
$1.54B
Enterprise Value
$1.65B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 92%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.novocure.com
HQ Baar
Employees 1,605
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$5
$6
$8
Current: $13.21 -51% vs base

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$655.4M
8.3%%
Gross Profit
$488.5M
4.4%%
Operating Income (GAAP)
-$153.8M
9.8%%
EBITDA
-$104.6M
4.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
74.5%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating NovoCure Limited's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
60
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.76). This signals strong consumable attach-rate economics.
  • Stable Gross Margin Profile Gross margin stability is strong (score 0.71). Low volatility confirms durable consumable pricing.

Key risks

  • Elevated Leverage Leverage is elevated vs peers (score 0.28). High net debt/EBITDA limits the balance sheet's acquisition firepower.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
74
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing NVCR's balance between Growth (34.5%), Profitability (37.4%), and Safety (28.1%). Growth 34% Safety 28% Profitability 37%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

48th percentile vs peers
49
Key Signals
Rev Growth YoY 8.3% 54p Revenue CAGR 3Y 6.8% 51p EPS Growth YoY 21.9% 48p Asset Growth YoY -35.2% 6p
Strengths
  • Gross Profit Margin in top 20% of peers (74.5%, 82th percentile)
Risks

No significant risks identified for this axis.

Profitability

53th percentile vs peers
53
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

39th percentile vs peers
40
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for NovoCure Limited.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$6.48
- - -
-50.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000